Gates MR - Search Results

1

Mass Balance, Metabolic Pathways, Absolute Bioavailability, and Pharmacokinetics of Giredestrant in Healthy Subjects.

Kshirsagar S, Chen YC, Yu J, Gates MR, Kawakatsu S, Khojasteh SC, Ma S, Musib L, Malhi V, Osaghae U, Wang J, Cho S, Tang YT, Zhang D, Zhao W, De Bruyn T. Kshirsagar S, et al. Among authors: gates mr. Drug Metab Dispos. 2024 Jul 16;52(8):847-857. doi: 10.1124/dmd.124.001688. Drug Metab Dispos. 2024. PMID: 38834357

2

Absorption, Metabolism, Excretion, and the Contribution of Intestinal Metabolism to the Oral Disposition of [14C]Cobimetinib, a MEK Inhibitor, in Humans.

Takahashi RH, Choo EF, Ma S, Wong S, Halladay J, Deng Y, Rooney I, Gates M, Hop CE, Khojasteh SC, Dresser MJ, Musib L. Takahashi RH, et al. Drug Metab Dispos. 2016 Jan;44(1):28-39. doi: 10.1124/dmd.115.066282. Epub 2015 Oct 8. Drug Metab Dispos. 2016. PMID: 26451002 Clinical Trial.

3

Optimizing Early-stage Clinical Pharmacology Evaluation to Accelerate Clinical Development of Giredestrant in Advanced Breast Cancer.

Malhi V, Agarwal P, Gates MR, Liu L, Wang J, De Bruyn T, Lam S, Eng-Wong J, Perez-Moreno P, Chen YC, Yu J. Malhi V, et al. Among authors: gates mr. Cancer Res Commun. 2023 Dec 15;3(12):2551-2559. doi: 10.1158/2767-9764.CRC-23-0324. Cancer Res Commun. 2023. PMID: 38019116 Free PMC article. Clinical Trial.

4

Application of a Novel 'Make and Test in Parallel' Strategy to Investigate the Effect of Formulation on the Pharmacokinetics of GDC-0810 in Healthy Subjects.

Cheeti S, Hou HH, Nelson E, Walker H, Chen B, Morley R, Gates M, Musib L, Girish S, Sahasranaman S, Liu L. Cheeti S, et al. Pharm Res. 2018 Oct 15;35(12):233. doi: 10.1007/s11095-018-2516-0. Pharm Res. 2018. PMID: 30324422 Free PMC article. Clinical Trial.

5

Correction to: Application of a Novel 'Make and Test in Parallel' Strategy to Investigate the Effect of Formulation on the Pharmacokinetics of GDC-0810 in Healthy Subjects.

Cheeti S, Hou HH, Nelson E, Walker H, Chen B, Morley R, Gates M, Musib L, Girish S, Sahasranaman S, Liu L. Cheeti S, et al. Pharm Res. 2018 Oct 26;35(12):244. doi: 10.1007/s11095-018-2529-8. Pharm Res. 2018. PMID: 30367284 Free PMC article.

6

Phase Ia/b Study of Giredestrant ± Palbociclib and ± Luteinizing Hormone-Releasing Hormone Agonists in Estrogen Receptor-Positive, HER2-Negative, Locally Advanced/Metastatic Breast Cancer.

Jhaveri KL, Bellet M, Turner NC, Loi S, Bardia A, Boni V, Sohn J, Neilan TG, Villanueva-Vázquez R, Kabos P, García-Estévez L, López-Miranda E, Pérez-Fidalgo JA, Pérez-García JM, Yu J, Fredrickson J, Moore HM, Chang CW, Bond JW, Eng-Wong J, Gates MR, Lim E. Jhaveri KL, et al. Among authors: gates mr. Clin Cancer Res. 2024 Feb 16;30(4):754-766. doi: 10.1158/1078-0432.CCR-23-1796. Clin Cancer Res. 2024. PMID: 37921755 Free PMC article. Clinical Trial.

7

Effect of OATP1B1/1B3 Inhibitor GDC-0810 on the Pharmacokinetics of Pravastatin and Coproporphyrin I/III in Healthy Female Subjects.

Liu L, Cheeti S, Yoshida K, Choo E, Chen E, Chen B, Gates M, Singel S, Morley R, Ware J, Sahasranaman S. Liu L, et al. J Clin Pharmacol. 2018 Nov;58(11):1427-1435. doi: 10.1002/jcph.1261. Epub 2018 May 22. J Clin Pharmacol. 2018. PMID: 29786857

8

Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors.

Shapiro GI, LoRusso P, Kwak E, Pandya S, Rudin CM, Kurkjian C, Cleary JM, Pilat MJ, Jones S, de Crespigny A, Fredrickson J, Musib L, Yan Y, Wongchenko M, Hsieh HJ, Gates MR, Chan IT, Bendell J. Shapiro GI, et al. Among authors: gates mr. Invest New Drugs. 2020 Apr;38(2):419-432. doi: 10.1007/s10637-019-00776-6. Epub 2019 Apr 24. Invest New Drugs. 2020. PMID: 31020608 Clinical Trial.

9

Giredestrant reverses progesterone hypersensitivity driven by estrogen receptor mutations in breast cancer.

Liang J, Ingalla ER, Yao X, Wang BE, Tai L, Giltnane J, Liang Y, Daemen A, Moore HM, Aimi J, Chang CW, Gates MR, Eng-Wong J, Tam L, Bacarro N, Roose-Girma M, Bellet M, Hafner M, Metcalfe C. Liang J, et al. Among authors: gates mr. Sci Transl Med. 2022 Sep 21;14(663):eabo5959. doi: 10.1126/scitranslmed.abo5959. Epub 2022 Sep 21. Sci Transl Med. 2022. PMID: 36130016

10

An Open-label Phase I Study of GDC-0927 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer.

Chandarlapaty S, Dickler MN, Perez Fidalgo JA, Villanueva-Vázquez R, Giltnane J, Gates M, Chang CW, Cheeti S, Fredrickson J, Wang X, Collier A, Moore HM, Metcalfe C, Lauchle J, Humke EW, Bardia A. Chandarlapaty S, et al. Clin Cancer Res. 2023 Aug 1;29(15):2781-2790. doi: 10.1158/1078-0432.CCR-23-0011. Clin Cancer Res. 2023. PMID: 37261814 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

20 results

Search Page

Filters